Hunan maker of transdermal medicated patches and topical drugs sold through Chinese pharmacies.
Hunan maker of transdermal medicated patches and topical drugs sold through Chinese pharmacies.
In one line: A small Chinese medicated-patch maker.
Moat: narrow (brand). Established patch brand with pharmacy distribution, though a niche OTC category.
Headquarters: Changsha, Hunan, China · Employees: 1,291
Size Hunan Warrant Pharmaceutical (688799.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $725M, the 2818th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.16 on 18 Nov 2026.
Performance Over six months the shares fell 33.6%, against -7.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 2.6% over the last twelve months (peer median +0.7%); the operating margin is 9.5% (peer median 9.7%).
Valuation It trades at 47.6× forward earnings against a peer median of 13.7× (most expensive of 8).
Capital Return on invested capital runs 0.6 points below its cost of capital (6.0% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.38B | CN¥1.50B | CN¥1.39B | CN¥1.41B | CN¥1.28B |
| Revenue growth | — | +8% | -2% | +10% | — |
| Gross profit | CN¥823M | CN¥868M | CN¥820M | CN¥881M | CN¥844M |
| EBITDA | n/a | CN¥216M | CN¥205M | CN¥265M | CN¥216M |
| Net income | CN¥114M | CN¥238M | CN¥164M | CN¥211M | CN¥183M |
| Free cash flow | -CN¥182M | -CN¥202M | -CN¥91.4M | CN¥119M | CN¥36.5M |
| Capital expenditure | CN¥577M | CN¥520M | CN¥234M | CN¥106M | CN¥132M |
| Total debt | CN¥860M | CN¥507M | CN¥165M | CN¥24.2M | CN¥13.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hunan Warrant Pharmaceutical 688799.SS | $725M | -34% | -3% | 9% | 47.6× | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.25B | -7% | +4% | 10% | n/a | -2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688799.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.0% | -3.8% | 3rd lowest of 21 |
| 6-month return | -33.6% | -7.0% | 2nd lowest of 21 |
| Distance from 52-week high | -41.5% | -32.6% | 7th lowest of 21 |
| Revenue growth (TTM) | -2.6% | +0.7% | 8th lowest of 19 |
| Operating margin | 9.5% | 9.7% | 9th lowest of 19 |
| Forward P/E | 47.6× | 13.7× | most expensive of 8 |
| ROIC minus cost of capital | -0.6 pp | +1.2 pp | 6th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 16.7× | -2.0% | +26.1% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | n/a | -2.1% | 0.0% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | n/a | 9.4% | -1.4% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | n/a | 13.5% | -0.2% |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | n/a | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |